1. Home
  2. HQL vs FTH Comparison

HQL vs FTH Comparison

Compare HQL & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Life Sciences Investors Shares of Beneficial Interest

HQL

abrdn Life Sciences Investors Shares of Beneficial Interest

SELL

Current Price

$17.81

Market Cap

539.1M

Sector

Finance

ML Signal

SELL

Logo Faeth Therapeutics Inc. Common Stock

FTH

Faeth Therapeutics Inc. Common Stock

HOLD

Current Price

$9.23

Market Cap

507.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQL
FTH
Founded
1992
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
539.1M
507.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HQL
FTH
Price
$17.81
$9.23
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
★ $56.15
AVG Volume (30 Days)
102.6K
★ 672.4K
Earning Date
01-01-0001
11-03-2026
Dividend Yield
★ 11.56%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.79
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.17
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.66
$9.67
52 Week High
$22.67
$42.14

Technical Indicators

Market Signals
Indicator
HQL
FTH
Relative Strength Index (RSI) 44.90 25.41
Support Level $17.13 N/A
Resistance Level $18.58 $21.97
Average True Range (ATR) 0.67 2.02
MACD 0.04 -0.61
Stochastic Oscillator 26.26 3.13

Price Performance

Historical Comparison
HQL
FTH

About HQL abrdn Life Sciences Investors Shares of Beneficial Interest

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.

About FTH Faeth Therapeutics Inc. Common Stock

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Share on Social Networks: